Gastric Cancer

Article	Citations
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placeb	447
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastat	85
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)	83
Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma	79
Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE	71
Dietary intake of vitamin C and gastric cancer: a pooled analysis within the Stomach cancer Pooling (StoP) Project	56
Clinicopathological significance of microsatellite instability and immune escape mechanism in patients with gastric solid-type poorly differentiated adenocarcinoma	48
Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer	47
Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601	44
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer	42
Genomic landscape of a mouse model of diffuse-type gastric adenocarcinoma	38
Risk prediction model for gastric cancer within 5 years in healthy Korean adults	38
PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment	35
Subepithelial spread of early gastric cancer is common and extends more than expected	35
Sex-dependent different clinicopathological characterization of Epstein–Barr virus-associated gastric carcinoma: a large-scale study	29
Comparison of perioperative outcomes between bipolar sealing, ultrasonic shears and a hybrid device during laparoscopic gastrectomy for early gastric cancer: a prospective, multicenter, randomized stu	29
Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma	28
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plu	27
The putative pleiotropic functions of meprin β in gastric cancer	27
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study	27
Comment on “Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohor	25
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final a	25
Preclinical toxicological assessment of amido-bridged nucleic acid-modified antisense oligonucleotides targeting synaptotagmin XIII for intra-abdominal treatment of peritoneal metastasis of gastric ca	25
Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy	25
Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study	24

A comparative study of demarcation line diagnostic performance between non-magnifying observation with white light and non-magnifying observation with narrow-band light for early gastric cancer	23
A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan	23
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan	23
Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma	23
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry	22
Leukaemia inhibitory factor in gastric cancer: friend or foe?	22
Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study	21
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials	21
Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer	21
Helicobacter pylori and gastric cancer: a lysosomal protease perspective	21
Sustained exposure to Helicobacter pylori induces immune tolerance by desensitizing TLR6	20
Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study	20
ATF4-mediated circTDRD3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-891b/ITGA2 axis and AKT signaling pathway	20
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)	19
SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review	19
Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer	19
Improved survival after laparoscopic compared to open gastrectomy for advanced gastric cancer: a Swedish population-based cohort study	19
Gastric microbiome signature for predicting metachronous recurrence after endoscopic resection of gastric neoplasm	19
Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination	19
Soluble factors in malignant ascites promote the metastatic adhesion of gastric adenocarcinoma cells	19
Diagnosing and grading gastric atrophy and intestinal metaplasia using semi-supervised deep learning on pathological images: development and validation study	19
Statin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma: a Swedish population-based cohort study	18
Endoscopic differential diagnosis between foveolar-type gastric adenoma and gastric hyperplastic polyps in Helicobacter pylori-naïve patients	18
Acknowledgment to Reviewers	18
Ethnic-specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations	17
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial	17
A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013)	16
Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer	16
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience	16
Incidence and risk factors of tuberculosis in patients following gastrectomy or endoscopic submucosal dissection: a cohort analysis of country-level data	16
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS	16
Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab	15
Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor–adipocyte interaction indicating an altered immune response	15
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study	15
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world	15
LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA	15
Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemothe	14
Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis	14
A deep-learning based system using multi-modal data for diagnosing gastric neoplasms in real-time (with video)	14
Automatic surgical phase recognition-based skill assessment in laparoscopic distal gastrectomy using multicenter videos	14
Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism	13
Predicting chemotherapy responsiveness in gastric cancer through machine learning analysis of genome, immune, and neutrophil signatures	13
Dose–response association between cigarette smoking and gastric cancer risk: a systematic review and meta-analysis	13
Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)	13
Early gastric cancer with RhoGAP fusion is linked to frequent nodal metastasis and a part of microtubular–mucocellular histology	12
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)	12
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy	12
National guidelines for gastric cancer: redundant or needed?	12
Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry stomach cancer subcohort	12
Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition	12

Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis	12
Prophylactic laparoscopic total gastrectomy for gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): the first report in Asia	12
Treatment response after palliative radiotherapy for bleeding gastric cancer: a multicenter prospective observational study (JROSG 17-3)	12
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast	12
Comment on: “Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study. Gastric cancer, 2021 Aug 5” by Kim et al.	11
The clinical importance of the host anti-tumour reaction patterns in regional tumour draining lymph nodes in patients with locally advanced resectable gastric cancer: a systematic review and meta-anal	11
Tumor infiltration of inactive CD8 + T cells was associated with poor prognosis in Gastric Cancer	11
LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer	11
Nishi memorial award in gastric cancer	11
Hypoxia associated lncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK14	11
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial	11
Family history and gastric cancer incidence and mortality in Asia: a pooled analysis of more than half a million participants	11
Global burden of young-onset gastric cancer: a systematic trend analysis of the global burden of disease study 2019	11
EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein–Barr virus-associated gastric cancer	11
Reply to the letter by Junjie Jiang et al. regarding our manuscript “Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study”	11
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer	10
Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions	10
Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer	10
Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”	10
Advantages of adjuvant chemotherapy using S-1 following minimally invasive gastrectomy for gastric cancer versus open surgery: a propensity score-matched analysis	10
Diagnostic performance of deep-learning-based virtual chromoendoscopy in gastric neoplasms	10
Minimum resection length to ensure a pathologically negative distal margin and a larger remnant stomach for esophagogastric junction cancer	10
Clinical epidemiology of the endoscopic, laparoscopic, and surgical resection of malignant gastric tumors in Japan, 2014–2021: a retrospective study using open data from a national claims database	10
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)	10
N6-methyladenosine-modified MIB1 promotes stemness properties and peritoneal metastasis of gastric cancer cells by ubiquitinating DDX3X	10
Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01)	10
New response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor	10
The clinical impact of frailty on the postoperative outcomes of patients undergoing gastrectomy for gastric cancer: a propensity-score matched database study	9
Insulin and the insulin receptor collaborate to promote human gastric cancer	9
A machine learning model for predicting the lymph node metastasis of early gastric cancer not meeting the endoscopic curability criteria	9
Outcomes after gastrectomy according to the Gastrectomy Complications Consensus Group (GCCG) in the Dutch Upper GI Cancer Audit (DUCA)	9
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (M	9
Molecular profile of poorly cohesive gastric carcinoma with special reference to survival	9
Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study	9
rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in Helicobacter pylori–infected individuals: a genome-wide association study in the Korean population	9
Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric	9
Oncological impact of unexpected horizontal tumor spread in gastric cancer that requires total gastrectomy	9
FHOD1 and FMNL1 formin proteins in intestinal gastric cancer: correlation with tumor-infiltrating T lymphocytes and molecular subtypes	9
Comment on: Statin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma: a Swedish population-based cohort study	9
Development and evaluation of a double-check support system using artificial intelligence in endoscopic screening for gastric cancer	9
Circulating hormones and risk of gastric cancer by subsite in three cohort studies	8
Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study	8
Artificial intelligence-based diagnosis of upper gastrointestinal subepithelial lesions on endoscopic ultrasonography images	8
Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study	8
Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma	8
Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis	8
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit	8
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma	8
Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression	7
Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models	7
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape	7
A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics	7
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors	7
Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance	7
Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia	7
Accuracy of upper endoscopies with random biopsies to identify patients with gastric premalignant lesions who can safely be exempt from surveillance	7
Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer	7
Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape	6
Correction to: DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial–mesenchymal transition in gastric cancer	6
Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice	6
Comment on: “Internal hernia after gastrectomy for gastric cancer in minimally invasive surgery era,” Gastric Cancer, 2019 Feb 13, by Kang et al	6
Discrepant effect of high-density lipoprotein cholesterol on esophageal and gastric cancer risk in a nationwide cohort	6
Correction to: A multi-mode Wnt- and stemness-regulatory module dictated by FOXM1 and ASPM isoform I in gastric cancer	6
Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study	6
Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation	6
Clinical advantage of standardized robotic total gastrectomy for gastric cancer: a single-center retrospective cohort study using propensity-score matching analysis	6
Ethnic‑specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations	6
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy	6
Complete one-to-one correspondence between magnifying endoscopic and histopathologic images: the KOTO method II	6
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study	6
Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor	6
Short- and long-term oncological outcomes of totally laparoscopic gastrectomy versus laparoscopy-assisted gastrectomy for clinical stage I gastric cancer	6
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models	6
Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer	5
The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration	5
The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry	5
Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer	5
Proteomic profiling of gastric cancer with peritoneal metastasis identifies a protein signature associated with immune microenvironment and patient outcome	5
Brain metastases in gastroesophageal cancers—an underestimated complication	5
Risk factors for the failure of endoscopic resection of gastric submucosal tumors: a long-term retrospective case–control study	5

CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions	5
miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer	5
Collagen-related gene expression level predicts the prognosis and immune therapy response	5
Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy	5
Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial	5
Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer	5
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective	5
Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study	5
Development of a predictive model for extragastric recurrence after curative resection for early gastric cancer	5
Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, g	5
Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case–control study	5
CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6	5
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma	4
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer	4
SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score–matched analysis	4
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients	4
CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma	4
Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy	4
FAK/IL-8 axis promotes the proliferation and migration of gastric cancer cells	4
Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials	4
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07	4
Safety and feasibility of single-incision laparoscopic distal gastrectomy in overweight and obese gastric cancer patients: a propensity score-matched analysis	4
Remission of type 2 diabetes after gastrectomy for gastric cancer: diabetes prediction score	4
Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy	4
Reply to letter to the editor: “5-year follow-up results of a JCOG1104 (OPAS-1) phase III noninferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II	4
Cross-phenotype association analysis of gastric cancer: in-silico functional annotation based on the disease–gene network	4
Personalized therapeutic strategies in HER2-driven gastric cancer	4
Clinical and endoscopic features of metachronous gastric cancer with possible lymph node metastasis after endoscopic submucosal dissection and Helicobacter pylori eradication	4
Impact of chemotherapy delay on long-term prognosis of laparoscopic radical surgery for locally advanced gastric cancer: a pooled analysis of four randomized controlled trials	4
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies	4
Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based	4
Application value of overlap guiding tube (OGT) in assisting overlap esophagojejunostomy during laparoscopic total gastrectomy for gastric/gastroesophageal junction (G/GEJ) tumors	4
CD45− erythroid progenitor cells promote lymph node metastasis in gastric cancer by inducing a hybrid epithelial/mesenchymal state in lymphatic endothelial cells	4
Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma	4
Patient metabolic profile defined by liver and muscle 18F-FDG PET avidity is independently associated with overall survival in gastric cancer	4
Correction: Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer	3
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 ra	3
Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gast	3
Survival trends in gastric cancer patients between 1987 and 2016: a population-based cohort study in Finland	3
Effect of preoperative chemotherapy on the histopathological classification of gastric cancer	3
Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis	3
A Japanese family of hereditary diffuse gastric cancer with a germline pathogenic variant of CTNN1A detected via comprehensive genome profiling	3
Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach	3
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric juncti	3
Expression of therapy target molecules in esophagogastric junction and Barrett’s adenocarcinoma	3
FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1	3
Robotic gastrectomy for gastric cancer: systematic review and future directions	3
Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study	3
Limitations of the cox proportional hazards model and alternative approaches in metachronous recurrence research	3
Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression	3
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023	3
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma	3
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression	3
Correction to: Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation	3
Genomic events stratifying prognosis of early gastric cancer	3
EPRS/GluRS promotes gastric cancer development via WNT/GSK-3β/β-catenin signaling pathway	3
Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer	3
Proteomics signature of autoimmune atrophic gastritis: towards a link with gastric cancer	3
Nishi Memorial Award in Gastric Cancer	3
Differential impact of frailty on surgical and non-surgical site complications in patients with gastric cancer undergoing gastrectomy	3
Short-term outcomes of preoperative computed tomography angiography versus standard assessment in patients with BMI ≥ 25.0 kg/m2 undergoing laparoscopic gastrectomy: the GISSG20-01 randomized clinical	3
Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)	3